These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6840173)

  • 1. Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.
    Rosenkranz B; Fischer C; Jakobsen P; Kirstein Pedersen A; Frölich JC
    Eur J Clin Pharmacol; 1983; 24(2):231-5. PubMed ID: 6840173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part II: Multiple dose study.
    Kuo BS; Ritschel WA
    Biopharm Drug Dispos; 1987; 8(1):11-21. PubMed ID: 3580509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New metabolites of sulfinpyrazone in man.
    Dieterle W; Faigle JW; Moppert J
    Arzneimittelforschung; 1980; 30(6):989-93. PubMed ID: 7191279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.
    Schlicht F; Staiger C; de Vries J; Gundert-Remy U; Hildebrandt R; Harenberg J; Wang NS; Weber E
    Eur J Clin Pharmacol; 1985; 28(1):97-103. PubMed ID: 3987792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics and metabolism of sulfinpyrazone.
    Mahony C; Wolfram KM; Nash PV; Bjornsson TD
    Clin Pharmacol Ther; 1983 Apr; 33(4):491-7. PubMed ID: 6831828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the gut flora in the reduction of sulfinpyrazone in humans.
    Strong HA; Oates J; Sembi J; Renwick AG; George CF
    J Pharmacol Exp Ther; 1984 Sep; 230(3):726-32. PubMed ID: 6470977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing.
    Pedersen AK; FitzGerald GA
    Clin Pharmacol Ther; 1985 Jan; 37(1):36-42. PubMed ID: 3917387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human platelet cyclo-oxygenase activity by sulfinpyrazone and three of its metabolites.
    Del Maschio A; Livio M; Cerletti C; De Gaetano G
    Eur J Pharmacol; 1984 Jun; 101(3-4):209-14. PubMed ID: 6432556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part I: Single dose study.
    Ritschel WA; Kuo BS
    Biopharm Drug Dispos; 1987; 8(1):1-9. PubMed ID: 3107626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.
    Bradbrook ID; John VA; Morrison PJ; Rogers HJ; Spector RG
    Br J Clin Pharmacol; 1982 Feb; 13(2):177-85. PubMed ID: 7059415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man.
    Dieterle W; Faigle JW; Mory H; Richter WJ; Theobald W
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):135-45. PubMed ID: 786687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites.
    He M; Kunze KL; Trager WF
    Drug Metab Dispos; 1995 Jun; 23(6):659-63. PubMed ID: 7587949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-performance liquid chromatographic analysis of sulfinpyrazone and its metabolites in biological fluids.
    Bjornsson TD; Wolfram KM; Routledge PA; Shand DG
    J Chromatogr; 1980 Mar; 181(3-4):417-25. PubMed ID: 7391155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of sulfinpyrazone and four metabolites in plasma and urine by high pressure liquid chromatography.
    Lentjes EG; Tan Y; Van Ginneken CA
    Pharm Weekbl Sci; 1985 Dec; 7(6):252-9. PubMed ID: 4080510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-performance liquid chromatographic determination of sulfinpyrazone and its metabolites in plasma.
    Kuo BS; Kaplan LA; Ritschel WA
    Arzneimittelforschung; 1984; 34(5):548-50. PubMed ID: 6540568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of sulfinpyrazone and its metabolites in human serum and in solutions of human serum albumin.
    Jakobsen P; Pedersen AK; Andreasen F
    Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):243-9. PubMed ID: 7136730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species differences in the disposition and metabolism of sulfinpyrazone.
    Dieterle W; Faigle JW
    Xenobiotica; 1981 Aug; 11(8):559-68. PubMed ID: 7303725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo.
    Pay GF; Wallis RB; Zelaschi D
    Haemostasis; 1981; 10(3):165-75. PubMed ID: 7262645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of two different dosage regimens of sulphinpyrazone on platelet function ex vivo and blood chemistry in man.
    Maguire ED; Pay GF; Turney J; Wallis RB; Weston MJ; White AM; Williams LC; Woods HF
    Haemostasis; 1981; 10(3):153-64. PubMed ID: 7262644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels and effects of sulfinpyrazone in patients requiring chronic hemodialysis.
    Bern MM; Cavaliere BM; Lukas G
    J Clin Pharmacol; 1980; 20(2-3):107-16. PubMed ID: 7381028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.